VIVE Stock Overview
Designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Viveve Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0003 |
| 52 Week High | US$0.035 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 200.00% |
| 3 Month Change | -25.00% |
| 1 Year Change | -85.00% |
| 3 Year Change | -99.98% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Viveve to get US patent for technology to treat female stress urinary incontinence
Oct 04Viveve Medical receives patent for dual-energy technology in Taiwan
Jul 12Viveve under pressure after upsizes capital raise, prices offering at $3.40
Jan 14Viveve regains compliance with Nasdaq
Dec 17Viveve jumps 19% after FDA clearance for expansion of manufacturing treatment tips
Dec 03Shareholder Returns
| VIVE | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 200.0% | -3.4% | -3.5% |
| 1Y | -85.0% | 9.0% | 22.1% |
Return vs Industry: VIVE underperformed the US Medical Equipment industry which returned 9% over the past year.
Return vs Market: VIVE underperformed the US Market which returned 22.1% over the past year.
Price Volatility
| VIVE volatility | |
|---|---|
| VIVE Average Weekly Movement | 19,687.6% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VIVE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VIVE's weekly volatility has increased from 15358% to 21470% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | n/a | www.viveve.com |
Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally.
Viveve Medical, Inc. Fundamentals Summary
| VIVE fundamental statistics | |
|---|---|
| Market cap | US$10.00 |
| Earnings (TTM) | -US$28.13m |
| Revenue (TTM) | US$6.83m |
0.0x
P/S Ratio0.0x
P/E RatioIs VIVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIVE income statement (TTM) | |
|---|---|
| Revenue | US$6.83m |
| Cost of Revenue | US$5.71m |
| Gross Profit | US$1.12m |
| Other Expenses | US$29.25m |
| Earnings | -US$28.13m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did VIVE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 22:33 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Viveve Medical, Inc. is covered by 14 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Haynor | Alliance Global Partners |
| Gregory Chodaczek | B. Riley Securities, Inc. |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |